MEDI logo

Medistim ASA Stock Price

OB:MEDI Community·NOK 4.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 20 Fair Values set on narratives written by author

MEDI Share Price Performance

NOK 230.00
19.00 (9.00%)
NOK 310.00
Fair Value
NOK 230.00
19.00 (9.00%)
25.8% undervalued intrinsic discount
NOK 310.00
Fair Value
Price NOK 230.00
AnalystLowTarget NOK 310.00
AnalystConsensusTarget NOK 315.00
AnalystHighTarget NOK 320.00

MEDI Community Narratives

·
Fair Value NOK 310 25.8% undervalued intrinsic discount

Rising Cost Pressures And Declining Patient Pools Will Curtail Potential

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value NOK 315 27.0% undervalued intrinsic discount

Share Repurchases and Market Expansion Will Support Stronger Future Performance

1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value NOK 320 28.1% undervalued intrinsic discount

Aging Global Populations And INTUI Upgrades Will Expand Adoption

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
NOK 315
27.0% undervalued intrinsic discount
Revenue
8.14% p.a.
Profit Margin
22.06%
Future PE
34.65x
Price in 2029
NOK 379.29
NOK 310
25.8% undervalued intrinsic discount
Revenue
10.06% p.a.
Profit Margin
23.5%
Future PE
32.9x
Price in 2029
NOK 373.48

Trending Discussion

Updated Narratives

MEDI logo

MEDI: Clinical Trial Momentum And Dividend Visibility Will Support Future Performance

Fair Value: NOK 315 27.0% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MEDI logo

MEDI: Higher Profitability And Lower Discount Rate Will Support Stronger Future P/E

Fair Value: NOK 310 25.8% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
MEDI logo

MEDI: Stable Fair Value And Margins Will Support Future Upside

Fair Value: NOK 320 28.1% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Outstanding track record with flawless balance sheet.

1 Risk
3 Rewards

Medistim ASA Key Details

NOK 719.9m

Revenue

NOK 138.8m

Cost of Revenue

NOK 581.1m

Gross Profit

NOK 425.0m

Other Expenses

NOK 156.1m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 19, 2026
8.53
80.71%
21.68%
0%
View Full Analysis

About MEDI

Founded
1984
Employees
159
CEO
Kari Krogstad
WebsiteView website
www.medistim.com

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and ultrasound imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.

Recent MEDI News & Updates

Narrative Update May 25

MEDI: Clinical Trial Momentum And Dividend Visibility Will Support Future Performance

Analysts have kept Medistim's fair value estimate steady at NOK 315.0. This reflects slightly updated assumptions on discount rate, revenue growth, profit margin and future P/E, without a change in their overall price target stance. What's in the News Medistim ASA plans a board meeting on February 26, 2026, to consider and resolve the annual general meeting and an ordinary dividend for 2025 (company announcement).

Recent updates

No updates

Medistim ASA Competitors